Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche wins EU approval for leukemia drug
The approval is based on compelling results from the pivotal Phase III study CLL8, the company said. According to Roche, the results showed that patients receiving MabThera in
The approval is based on compelling results from the pivotal Phase III study CLL8, the company said. According to Roche, the results showed that patients receiving MabThera in
Ark said that the discovery, which was made by its scientists in Finland, represents a major advance on existing RNA silencing technology and has the potential for use
According to the company, both the IN Apomorphine and IN Diazepam Phase I studies showed high bioavailability, positive pharmacokinetics and good tolerability and confirmed that each candidate has
The new agreement extends through December 2009. The International AIDS Vaccine Initiative (IAVI) and the St Stephen’s AIDS Trust at the Chelsea and Westminster Hospital have initiated a
This Phase IIa, double-blind, placebo-controlled study will enroll up to 150 subjects with type 2 diabetes who are currently being treated with basal insulin and oral anti-diabetes agents.
The sites are Florida Hospital/Cardiovascular Institute – Orlando Florida and Chandler Regional Medical Center and Mercy Gilbert Medical Center – Phoenix Arizona metropolitan area. Mercy Hospital Fairfield (Ohio)
According to Gentronix, GreenScreen HC is the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive
IC14 is a clinical stage recombinant chimeric monoclonal antibody which recognizes and blocks the function of human CD14, an essential component of the innate inflammatory response to bacterial
Glufast, originally created and developed by Kissei, co-marketed in tandem with Takeda in Japan since May 2004, is a diabetic medicine that promotes insulin secretion by stimulating the
Medipattern has recently signed an agreement with GE Healthcare to create a set of image quantification tools to help physicians visualize plaque and other conditions that can block